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The delivery of drugs by inhalation is an integral component of asthma and chronic
obstructive pulmonary disease (COPD) management. However, even with effective inhaled
pharmacological therapies, asthma, particularly, remains poorly controlled around the
world. The reasons for this are manifold, but limitations of treatment guidelines in terms
of content, implementation and relevance to everyday clinical life, including insufficient
patient education, access to health care and cost of medication as well as poor inhaler
technique are likely to contribute. Considering that inhalation therapy is a cornerstone in
asthma and COPD management, little advice is provided in the guidelines regarding inhaler
selection. The pressurised metered dose inhaler (pMDI) is still the most frequently
prescribed device worldwide, but even after repeated tuition many patients fail to use it
correctly. In addition, the correct technique can be lost over time. Although several
improvements in pMDIs such as a change in the propellant and actuation have resulted in
improvements in lung deposition, many dry powder inhalers (DPIs) are easier to use.
However, these devices also have limitations such as dependency of drug particle size on
flow rate and loss of the metered dose if the patient exhales through the device beforePublished by Elsevier Ltd.
bon; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FDA, Food and Drug
e; ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1 s; GINA, Global Initiative for
pMDI, pressurised metered dose inhaler
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Improved asthma and COPD management 11inhaling. Improvements in using inhalation devices more efficiently, in inhaler design for
supporting patient compliance, and advances in inhaler technology to assure drug delivery
to the lungs, have the potential to improve asthma and COPD management and control.
New and advanced devices are considered being helpful to minimise the most important
problems patients have with current DPIs.
& 2007 Published by Elsevier Ltd.Contents
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Inhalation is the preferred route of delivery for anti-asthma
and chronic obstructive pulmonary disease (COPD) drugs. As
therapeutic agents are delivered directly to the lungs, the
inhaled route offers a more rapid onset of action, allows
smaller doses to be used and has a better efficacy to safety
ratio compared to systemic therapy. Long-acting b2-agonists
(LABAs) and inhaled corticosteroids (ICSs) have become the
pharmacological mainstay of management programmes,
treating the symptoms of disease and the underlying
inflammatory processes, respectively. Pharmacotherapy
has advanced to such a degree that the goals of treatment,
as outlined by the international treatment guidelines Global
Initiative for asthma (GINA), expect asthma sufferers to be
managed so that they can live normal lives with little or no
symptoms, have no exacerbations, minimal need for reliever
medication, normal lung function and no side effects.1
However, the current level of asthma control worldwide
falls short of these goals for long-term management.1
Despite the availability of effective therapies, asthma
remains an illness that is insufficiently controlled.2–4 Many
patients with typical symptoms of asthma complain of
wheezing, chest tightness, cough, breathlessness, asthma-
related sleep disturbance and require unscheduled urgent
care visits and emergency hospital admission due to asthma
exacerbations.2–4 In Eastern Europe and particularly in the
Asiatic-Pacific region, hospitalisation and emergency admis-
sion rates remain the highest4 (Figure 1). Even patients who
feel well still complain of symptoms providing evidence that
they under-estimate their own symptoms.2 Asthmatic
patients may also not follow GINA recommendations for
medication use,3 highlighted by the fact that only 26% and9% of severe-persistent patients in Western Europe and
Japan, respectively, used anti-inflammatory preventive
medication.4 Thus, asthma control remains a public health
problem with variation not only among individuals but also
across the socioeconomic spectrum. Patient education,
access to health care and the cost of medications are likely
to influence treatment results. Not all patients achieve
reasonable control with the currently available medication,
but there is little evidence to suggest that new drugs which
are currently under development will put the disease in
complete remission in the majority of patients.
From clinical practice as well as from observational
studies, however, it is evident that a poor pressurised
metered dose inhaler (pMDI) technique leads to poor
treatment responses.5–7 Any improvement in inhalation
therapy therefore has the potential to improve outcomes
of asthma therapy without introducing costly new treatment
modalities. This review will, therefore, assess problems that
can lead to poor inhaler techniques, which could contribute
to poor asthma control. It will also summarise the many
problems facing patients when using a pMDI, outline the
generic advantages dry powder inhalers (DPIs) have over
pMDIs and discuss individual limitations of DPIs currently on
the market. In particular, the reliance of DPIs on inspiratory
effort, the relationship between inspiratory effort and drug
particle size, the significance of particle size and inspiratory
speed on clinical effect and the theory that ideal particle
size depends on drug class are discussed. Characteristic of
an ideal inhaler device and what criteria are important for
clinicians to know when selecting devices for individual
patients are considered. Finally, the review shows the
opportunity for improved asthma control when using
advanced inhaler devices.
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Figure 1 Rates of clinic admissions and emergency admissions due to uncontrollable asthma exacerbations are unacceptably high
worldwide. Reprinted with permission from Ref. 2.
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Inhaled therapy, which was developed within the last
50 years, is, and will remain for the near future, the
cornerstone of asthma and COPD management. The first
reports about the effectiveness of inhaled therapy came from
as early as the beginning of the 20th century.8–10 However, this
therapy did not find widespread use until the middle of the
20th century after the introduction of the first propellant gas
dosing aerosols in the form of pMDIs. Unfortunately, con-
troversy surrounding the long-term use of regular b2-agonist
therapy emerged following epidemics of asthma deaths in the
UK and New Zealand in the late 1960s and late 1970s, which
were linked to the prescribing of high-dose isoprenaline and
fenoterol, respectively.11–14 Understandably, this brought the
safety of inhalation therapy into question.63 It was only after
the introduction of selective b2-mimetics and especially the
introduction of ICSs that topical treatment became the
therapy of choice for bronchial asthma and COPD.
However, the controversy regarding b2-agonists resurfaced
with the introduction into the market place of LABAs. Studies
reported a higher risk of mortality under LABA therapy,15–20
and the Food and Drug Administration (FDA) requested a
black box warning for these drugs. Additional data suggest
that ICSs must be dosed sufficiently high to guarantee
effective suppression of the underlying inflammatory pro-
cesses.1 Monotherapy with LABAs should be avoided.1
Several new technologies involving liquid nebulisation
have been developed for delivery of inhaled drugs, albeit for
conditions other than asthma. Their clinical value is
currently being established.
The key question: why is asthma so poorly
controlled?
There are many reasons why asthma remains poorly
controlled including underestimation of disease severity,
delay in diagnosis, undertreatment (e.g. delay in starting ICS
therapy), poor compliance with therapy, wrong inhalerchoice and inhalation technique, insufficient instructions
as well as ineffective guidelines. Failure to achieve asthma
control may be due to a discrepancy between individual
perceptions and the official definition of asthma control.21
This discrepancy suggests a communication gap between
health care providers and families, resulting in worse
asthma control than previously anticipated.2,3,21
Limitations of treatment guidelines
Both national and international treatment guidelines suffer
from many inherent limitations, which diminish their
relevance in everyday practice.22 The treatment guidelines
may not take account of individual differences in response
to treatment, neither can they take account of the
availability and cost of pharmacological treatments world-
wide. The evidence upon which they base their recommen-
dations comes from randomised controlled studies with
strict inclusion/exclusion criteria rather than from real life
data,22 and sometimes recommendations are consensus- and
not evidence-based.
Treatment guidelines do not provide adequate recom-
mendations on inhaler choice.1,23 The guidelines do state
that inhalers should be portable and simple to operate
(particularly important for children), should not require an
external power source, require minimal cooperation and
coordination and have minimal maintenance requirements.1
The British Thoracic Society guidelines also include patients’
preferences and the ability to correctly use the device as
issues to consider when choosing an inhaler.23 Surprisingly,
despite the well-documented problems with pMDI devices,
GINA recommends pMDIs for childreno4 years with a spacer
and face mask, for those aged 4–6 years with a spacer and
mouthpiece and for those 46 years with a spacer.1Poor inhaler technique
Inadequate inhaler instruction and poor inhaler technique
are another major cause of poor disease control, influencing
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Table 1 Frequent errors when using a pressurised
metered dose inhaler (pMDI) in patients beginning
inhalation therapy for the first time and in patients who
already use a pMDI.
pMDI error Number of
patients
No previous pMDI experience (n ¼ 135)
Actuation before inspiration 18
Actuation at end of inspiration 17
Actuation caused stop of inspiration 25
Actuated in mouth but inhaled through nose 14
Others 6
Total 80(59%)
Previous pMDI experience (n ¼ 1038)
Actuation before expiration 1
Actuation before inspiration 35
Actuation at end of inspiration 38
Actuation caused stop of inspiration 27
Actuated in mouth but inhaled through nose 12
Multiple actuations—same inhalation 17
Others 5
Total 135(13%)
Crompton.25
Improved asthma and COPD management 13as they do the amount of drug that reaches the lung and
compliance with therapy. Consequences of poor pMDI
technique include a decrease in pulmonary deposition,7
with a concomitant reduction in bronchodilator effect.6,7
Whereas the mechanisms of action, the effectiveness
and the significance of ICS as well as short- and long-acting
b2-agonists in the management of asthma and COPD are
well-established, the importance of the mode of delivery of
these agents, namely inhaler devices, is still disregarded,
despite being mandatory components of asthma manage-
ment.1,22 This is a regrettable situation since inhaled drugs
are the most effective therapy available for asthma and
COPD, improvements in inhaler technology and design in
combination with improvement in both physician and
patient education seems to be the way forward in improving
asthma management and control. In other words, an old
but well-known drug in a new, more reliable inhaler is
probably more useful than a new drug in an old (flawed)
inhaler.24
The pMDI is still the most frequently prescribed inhaler
device worldwide despite the fact that most patients cannot
use it correctly.25–31 This is because pMDIs require good
coordination of patient inspiration and inhaler activation to
ensure correct inhalation and deposition of drug in the
lung.25 Patients frequently fail to continuously inhale slowly
after activation of the inhaler and exhale fully before the
inhalation.32,64 In addition, patients often activate the
inhaler before inhalation or at the end of inhalation
and conclude inhaler activation while breath-holding.25,32
Several improvements in pMDIs such as a change in
the propellant and actuation/coordination, however, have
resulted in improvements in lung deposition.
A study of pMDI use in a group of 115 asthmatics showed
that 72% of patients who received no instruction were
unable to use their pMDI correctly compared with 48% after
physician training. Another study carried out in 207 patients
revealed that almost half of these patients (47%) used their
pMDI inadequately, women more frequently than men.31
Similarly, a Spanish study in patients, nurses and physicians
(n ¼ 1640)30 showed that 91% of patients were unable to use
their pMDI correctly compared with 85% and 72% of nurses
and physicians, respectively.
A series of studies performed by Crompton and colleagues
between 1982 and 2000 confirmed these findings.25,26,29
Inhaler technique was assessed after patients read the
inhaler package insert. Those patients who showed inade-
quate inhaler technique were instructed by trained person-
nel and then re-tested. In 1982, 54% of inhaler-naı¨ve out-
patients were unable to use a pMDI efficiently after reading
an instruction pamphlet or having the correct use of a pMDI
demonstrated to them.25 Common problems experienced by
patients using the pMDI included difficulty coordinating
aerosol release with inspiration (54%), stopping inhalation
upon release of the aerosol (24%) (cold Freon effect) and
inspiring through the nose whilst actuating the inhaler in the
mouth (12%) (Table 1).25 In subsequent studies, the
percentage of patients who could correctly use a pMDI after
reading the instruction pamphlet or after receiving instruc-
tion continued to fall. By 2000, only 21% of patients were
able to correctly use a pMDI after reading the package insert
and only 52% of patients correctly used a pMDI after
receiving instruction.27Unfortunately, previous ability to correctly use a pMDI is
not indicative of correct use during subsequent testing.25,33
A study from 1976 showed that 14% of patients, who had
documented evidence of correct inhaler technique, proved
to have totally inefficient coordination of inspiration and
dose release when their inhaler use was checked subse-
quently.33 Similarly, in a study carried out in 1982,25 13% of
patients already being treated with drugs by inhalation had
a poor inhaler technique, even though most had received
instruction on how to use a pMDI and were considered to be
able to use one of these devices correctly (Table 1). In a
large study (n ¼ 4078), 71% of patients were found to have
difficulty using pMDIs; almost half of the misuers had poor
coordination.5 This inhaler misuse was associated with poor
asthma control, with pMDI misusers having less stable
asthma control than good users (po0.001).
Even with the correct inhalation technique, pMDIs are
inefficient, often delivering less than 1/3 of the emitted
dose to the lungs34,35 and less than half of the emitted dose
to the peripheral airways compared with DPIs,34,36 with a
high proportion of drug being deposited in the mouth and
oropharynx34 which can cause local as well as systemic side
effects due to rapid absorption.37,38 Holding chambers can
compensate for many of the problems associated with MDIs
such as oropharyngeal drug deposition. Most of these holding
chambers are bulky and inconvenient, especially when they
need to be carried, which may reduce treatment compli-
ance. Pressurised MDIs also require an optimal inspiratory
flow, a full inspiration from functional residual capacity and
a breath hold of at least 6 s,15,16 and so intensive training
and regular technique re-testing are necessary.39 Finally,
unlike DPIs, pMDIs have no dose counters or inhalation
control mechanisms and, as they use propellant gases and
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J.C. Virchow et al.14dispersants, may cause cough, throat irritation and occa-
sionally paradoxical bronchoconstriction.40
These observations suggest that the pMDI is a difficult
device to use, with many asthmatic patients deriving
incomplete benefit from its use. Training apparently results
in a more efficient use of pMDIs, but these training sessions
must be repeated, and the results checked at regular
intervals by a member of medical staff. Substantial changes
in educational efforts are clearly required and should be
particularly addressed towards the general practitioner and
asthma nurse who in turn teach patients how to use their
inhaler device correctly. In order to derive maximum benefit
from inhalation therapy, it is necessary to select inhalation
devices that are reliable and simple to use by the patients,
and provide patient support in order to guarantee high
compliance especially with long-term therapy.
Therapeutic improvements due to technical
developments
The problem of coordination so regularly seen with pMDIs
was addressed in the 1970s and 1980s with the introduction
of the spacer device. These devices also reduced the
amount of drug deposited in the oropharynx, but they
suffered problems with electrostatic charge, needed to be
cleaned regularly and were bulky, making them cumbersome
to transport.41 A further advancement in pMDI technology
came in the form of a breath-activated pMDI, launched in
the UK in 1989, which precluded the need for patients to
coordinate device activation with inhalation. These breath-
activated inhalers were much easier for patients to use
correctly, but the occurrence of the cold freon effect was
still possible. By 1995 and the introduction of the Montreal
Protocol,42 use of chlorofluorocarbon (CFC) propellant gases
was banned and pharmaceutical companies replaced CFCs
with hydrofluorocarbons (hydrofluoroalkanes, HFAs).
The development of the DPI was an important progress in
the history of inhalation therapy. In general DPIs are easier
to use than most pMDIs. They do not require coordination of
inhaler actuation with inhalation. DPIs contain no propellant
gases, so they do not produce a cold Freon effect during
inhalation and are thus more environmentally friendly. The
first DPI appeared on the market in 1969 with the
introduction of the Spinhalers (Fisons, UK), followed by
the Rotahalers (GlaxoSmithKline, UK) in 1977 and the
Diskhalers (GlaxoSmithKline, UK) in 1980. The first multi-
dose gravity feed DPI, the Turbuhalers (AstraZeneca, UK),
was introduced in the UK in 1988, followed by the
Aerolizers (Novartis, Switzerland) and the Diskuss/Accu-
halers (GlaxoSmithKline, UK) and in 2001 the Novoli-
zers(MEDA, Sweden) (Table 2). While the first generation
of DPIs had to be cumbersomely re-loaded after each
individual dosage, the modern units are easily operated
multidose devices.
Limitations of DPIs
DPIs also suffer from some inherent limitations. For example,
the Spinhalers, Rotahalers, Handihalers (Boehringer-
Ingelheim, Germany) and Aerolizers require that single
doses are individually loaded into the inhaler immediatelybefore use. This is inconvenient for patients and does not
allow for direct dose counting. In addition, the inhalation
process sometimes has to be repeated until the capsule is
empty, which may give rise to underdosing and to high dose
variability. These devices contain no inhalation control
system and no feedback mechanism which reports effective
lung deposition. The Diskhalers is a multiple unit dose
device that has to be repeatedly loaded with a disc of
blisters. It needs frequent cleaning. The Diskuss is a 60-dose
device that uses a strip of foil drug containing blisters that
cannot be reloaded. Common patient errors when using
the Diskuss include using a slow inhalation at the start of the
inhalation manoeuvre, failure or difficulties to load
the device before inhalation and exhaling into the device.27
The Diskuss has a low intrinsic resistance, but, like the
Turbuhalers, does not have any triggering mechanism which
makes optimal drug delivery entirely dependant on an
individual patient’s uncontrolled inspiratory manoeuvre.
The Turbuhalers is a multidose or reservoir device. It has
several features that can generate uncertainty for both the
physician and the patient. There is a relatively high
variation in delivered dose,50,51 and the particle size
generated depends on the patients’ inspiratory flow rate.52
It is not easy to use by virtue of its high intrinsic resistance.
In addition, patients must inhale sharply through the
Turbuhalers at the beginning of the inhalation manoeuvre
to ensure disagglomeration of drug particles and hence
effective drug deposition.52 The device is not refillable,
there is no inhalation control mechanism and the dose
counter is limited. The amount of drug released from the
Turbuhalers can be reduced in conditions of high humid-
ity.53 Common patient errors when using the Turbuhalers
include slow inspiration, priming the device at 4451 from
the vertical position, failure to prime or difficulty priming
and exhaling into the device.27Factors affecting drug deposition properties of
DPIs
Sufficient inspiratory flow
The decisive factor for therapy success with DPIs is the
generation of sufficient inspiratory flow to trigger the
dosage and disagglomerate the powder to produce drug
particles of optimal size to reach the lungs. However, a
number of patients are unable to generate sufficient
inspiratory airflow to use their DPIs effectively, resulting in
poor drug release and low pulmonary deposition. This is
particularly the case for older patients (i.e. 460 years),
children and those patients with severe airflow limitation.
For example, using the ‘inhalation manager’, which
allocates an inhalation manoeuvre to the expected drug
delivery values, Kamin et al.54 showed that as many as 16.7%
of patients aged 18–59 years using the Diskuss had an
insufficient airflow which almost doubled to 31.5% in older
patients (60–99 years). The Turbuhalers fared less well
with 38.9% of 18–59-year olds and 66% of patients aged
60–99 years demonstrating insufficient inspiratory flow.54
The Novolizers has a low-to-medium intrinsic airflow
resistance, which allows it to be used by most school-aged
ARTICLE IN PRESS
Table 2 Summary of Novolizers clinical trial data.
Patient population Endpoint Main findings Reference
Peak inspiratory flow studies
Asthmatic children
(4–12 years)
PIF  All children capable of generating
sufficient inspiratory flow
Vogelberg et al.43
Asthmatic children
(6–11 years)
PIF, Novolizers vs
Turbuhalers
 Generated a higher PIF through the
Novolizers (92.7 vs 68.9 L/min)
Von Berg et al.44
Lung deposition
Healthy adult
volunteers
% Lung deposition in vivo,
Novolizers vs Turbuhalers
 At similar inspiratory flows, the
Novolizers and Turbuhalers achieve
similar lung deposition
 When used optimally, the Novolizers
deposits more drug in the lung and less in
the mouth than the Turbuhalers
Newman et al.34
Efficacy
COPD patients Efficacy of salbutamol,
Novolizers vs pMDI
 Novolizers and pMDI therapeutically
equivalent in terms of improvement in
lung function (21.3% vs 19.7% max %
increase in FEV1)
 78% patients rated Novolizers as very
good/good compared with 69% in pMDI
group
 Of previous pMDI users, 78% would rather
use a Novolizers
Kunkel and
Chuchalin45
Asthmatic patients Efficacy of budesonide,
Novolizers vs Turbuhalers
 Equivalent efficacy in terms of FEV1
improvement
Kunkel and
Chuchalin,45
Chuchalin et al.46
Asthmatic patients Efficacy of budesonide,
Novolizers vs Aerolizers
 Equivalent efficacy in terms of
bronchodilating effect
 Duration of action:X12 h for both devices
Richter et al.47,48
Asthmatic
patients, PMS
study
Efficacy, tolerability and
acceptance of the
Novopulmons Novolizers
 Improved lung function
 Reduced symptom severity
 Majority of patients preferred the
Novolizers of a pMDI or other DPI
 Likely to improve compliance
Mo¨ller et al.49
DPI: dry powder inhaler; FEV1: forced expiratory volume in 1 s; PIF: peak inspiratory flow; PMS: post-marketing surveillance; pMDI:
pressurised metered dose inhaler.
Improved asthma and COPD management 15children, elderly patients and those with severe airflow
obstruction.43,47,48Dependency of particle size on inspiratory flow
Particle size of drug generated by DPIs is another criterion
for success which should be considered as this has implica-
tions for drug deposition and clinical efficacy. With DPIs, the
respirable particle fraction and consequently drug deposi-
tion are dependent on inspiratory flow rate achieved by
the patient. This dependency has been clearly shown with
the Turbuhalers.52 If patients inhale maximally through theTurbuhalers at the beginning of the inhalation manoeuvre,
most of the emitted particles are between 1 and 6 mm in
diameter and so would be deposited within the lungs.
However, if patients inhale slowly at first and then gradually
increased the force of their inhalation as they progress, then
the size of emitted particles increases. In this scenario, most
of the particles are too large to inspire and so would be
deposited in the mouth and oropharynx.52
Furthermore, the significance of the inhalation speed
seems to vary with the particle size.55 While small particles
(i.e. 1.5 mm particle diameter) have a comparable effect on
the forced expiratory volume in 1 s (FEV1) regardless of the
inhalation speed, larger aerosol particles (i.e. 3 and 6 mm
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Figure 2 Effect of fast inhalation (shaded bars) compared with
slow inhalation (white bars) on forced expiratory volume in 1 s
(FEV1). *po0.001; +po0.05; ns ¼ not significant. Reprinted
with permission from Usmani et al.55
J.C. Virchow et al.16diameter) exert a greater bronchodilator effect when
inhaled at a slower speed (Figure 2).55 Slow inhalation
speed also resulted in a higher drug penetration index
regardless of drug particle size.55 This problem is avoided
with the Novolizers since the flow trigger valve system
releases drug powder only after a preset flow rate has been
achieved (35 L/min).56,57Ideal particle size?
The situation is further complicated by the discovery that
ideal particle size can vary depending on the inhaled active
ingredient class. Particle size can be adjusted to improve
delivery past the vocal cords. This could lead to a reduction
in the oral bioavailability. Theoretically, it could be more
important for beclomethasone than for fluticasone to have a
smaller MMAD. In addition, although a particle size that
increases more peripheral deposition might be desirable to
improve efficacy a clear clinical benefit has never been
demonstrated for this. Finally, an improved peripheral
deposition could raise safety concerns in patients with
minimal obstruction.58
The complexity of the issue of particle size is further
highlighted by the fact that b2-mimetics should ideally be
separated into relatively large aerosol particles (43–6mm),
which are mainly deposited in the large respiratory path-
ways where this substance class achieves its greatest
effect.55 Simultaneously, this could minimise the risk of
systemic side effects, since unlike larger particles, small
particles (o2.5mm diameter) are deposited mainly in
the alveoli where they exert no pharmacodynamic effect
and are rapidly absorbed, thus increasing the risk of
systemic adverse events.59 By comparison, it would probably
be beneficial to generate smaller particles in the case of
the ICS in order to reach the peripheral lung regions.
Therefore, altering intrapulmonary deposition through
aerosol particle size could enhance inhaled drug therapy
and might have clinical implications for developing
future inhaled treatments. The clinical relevance of this
hypothesis is not yet proven and should be further examined
in studies.Requirements for an ideal inhalation system
Fifty years of experience with inhalation systems has
enabled the concept of an ideal inhaler device to be
formulated.1. Simple handling is a mandatory requirement—particularly
for children.2. An inhalation unit should possess control mechanisms
which ensure:
(a) optimal respiratory flow at the time at which the
dosage is triggered
(b) a correct inhalation manoeuvre and
(c) allow the patient to verify successful completion of
the inhalation manoeuvre.
3. Both the released active ingredient dosage and the
deposition of the active ingredient in the lungs must be
sufficiently high and reproducible.4. There is a need for a dosage counter that counts not only
the dosages but also the correctly executed inhalations.
This characteristic would allow one to supervise com-
pliance.5. For reasons of environmental compatibility, modern units
should be free of propellant gas and be refillable.6. According to the GINA guidelines maintenance require-
ments must be minimal.17. Patient device preference should also be taken into
account.23
When selecting an inhalation device for a patient it is
useful to ask oneself the following questions60:1. In what device is the desired drug available and
affordable for the patient?2. Who will teach the patient the correct inhalation
technique?3. Does the patient have a preference for one type of
device, assuming that the device/drug combination is
available, affordable and can be handled correctly by the
patient after education?
When selecting an inhalation unit for an individual
patient, it is necessary to consider whether sufficient
inspiratory flow or an effective vital capacity manoeuvre is
possible for this patient (Figure 3). If the answer to this
question is ‘yes’ then an inhalation from a DPI would be
the device of choice or, alternatively, a breath-actuated
HFA-pMDI, possibly in combination with a spacer. If the
patients do not have a sufficient inspiratory capacity a
nebuliser or an HFA-pMDI and spacer with a valve are the
more suitable choice (Figure 3).61 Additionally, if possible,
different medications should be delivered from identical
devices. If individual combination therapy is unavoidable,
combinations of DPIs are preferable to an MDI and a DPI.62
Ideally, the prescribed inhaler should have a low-to-medium
airflow resistance and require minimal patient coordination.
Patient preference should also be taken into account where
there is a choice among several different inhalation systems.
Patients who have actively participated in and have
confidence in their inhaler choice are more likely to use it
regularly and correctly.
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Prescribing Aerosol-Therapy
1) All Medications from the same Device
2) Only CFC-free Aerosol-Devices 
3) Inspiratory Vital capacity-Maneuver possible? 
inhalation from tidal volume 
Nebulizer
or
HFA-pMDI + Spacer + Valve 
single breath inhalation 
Dry-Powder-Inhaler 
or
HFA-pMDI (+ Spacer) 
Yes No 
Figure 3 Prerequisites for the selection of an inhalation
system in an individual patient.
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The requirements that, according to the authors’ opinion,
are helpful to support optimal drug delivery from a metered
dose inhaler include that the device be breath-activated,
multidose and refillable with an inhalation control system
which indicates indirectly that deposition of the therapeutic
agent in the lungs has occurred. This can be achieved with a
flow trigger valve, which allows activation of the device and
releases the drug only when the required inspiratory flow
necessary for drug deposition in the lower airways is
reached.57 In addition, a dose meter that counts only
correctly performed inhalations might offer an advantage to
monitor patient compliance than one that records each
actuation of the device irrespective of whether the durg has
been properly inhaled or not. These features can overcome
some of the pitfalls of a poor patient inhalation technique
and poor patient compliance.
Conclusions
Improvements in the effectiveness, selectivity and safety of
inhaled pharmacological therapies have not yet produced a
concomitant improvement in asthma and COPD control. In
the near future, it seems unlikely that improvements in
disease control will be due to the introduction of new and
novel therapies, but rather from improvements in how these
pharmacological agents are delivered to the lung (i.e.
improvements in inhaler technology and design). The
problems associated with pMDI use have been well-docu-
mented. DPIs overcome many of the problems inherent in
pMDI design, but suffer from limitations of their own, most
notably a dependency on patients’ inspiratory flow to
generate an fine particle fraction suitable for deposition in
the lungs. When choosing an inhaler device for an individual
patient, it is important to check if patients are capable of
generating sufficient inspiratory flow, and where possible to
prescribe the same device to deliver all a patient’s
medication. Features of devices that help the patient to
perform correct inhalation assure drug delivery to the lungs.
Advanced devices may help to improve patients’ compliance
and thus improve asthma control.49Conflict of interest statements
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